GoodRx and Pharmacy Benefit Manager Antitrust Litigation (No. II)
The case involves economic causation theories typical of antitrust litigation, specifically alleging that GoodRx conspired with PBMs to suppress reimbursement rates for generic drugs, thereby harming competition and consumer access. Expert analysis under the Daubert standard is likely involved to establish causation and damages.
32
Pending actions
32
Total actions filed
Active
Status
04/02/2025
Established
Filing deadline
No specific filing deadlines or statutes of limitations are publicly documented in the available court filings. The ongoing procedural activity suggests that deadlines are being managed within the court's case schedule.
Who qualifies
Plaintiffs are nationwide independent pharmacies that have been reimbursed under the alleged scheme involving generic prescriptions. The conduct is alleged to be ongoing since early 2025, affecting transactions involving generic drugs reimbursed by PBMs in collusion with GoodRx.
Products involved
- Generic drugs (categories unspecified)
Alleged injuries
- Reduced reimbursement rates for independent pharmacies for generic prescriptions
- Financial harm to pharmacies and potential reduced access for consumers
Bellwether trials
No explicit recent updates on bellwether trial selections, specific trial dates, verdicts, or settlement conferences have been publicly reported since the last status conference scheduled for November 2025. Procedural activities continue into early 2026, but no definitive trial or settlement milestones are documented.
Settlement landscape
No specific settlement estimates or case values are publicly available. The case remains in procedural stages with ongoing case management and no reported settlement agreements or verdicts.
Lead counsel
- David Ko (Keller Rohrback)
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
